Arrowhead's ARO-MAPT Shows 73% Tau Reduction in Early Trial Data
Event summary
- ARO-MAPT achieved mean tau reduction of 73% in healthy volunteers at Day 105, with maximum reduction of 85%.
- Subcutaneous administration demonstrated durability with potential for quarterly dosing.
- Phase 1/2a study includes both healthy volunteers and early Alzheimer’s patients.
- No serious adverse events reported; most were mild injection-site reactions.
- Arrowhead plans to initiate trials for frontotemporal dementia and Progressive Supranuclear Palsy.
The big picture
Arrowhead’s success in delivering siRNA across the blood-brain barrier represents a major milestone in neurodegenerative disease treatment. The durable tau reduction in healthy volunteers validates the company’s TRiM platform, positioning it as a leader in RNAi therapeutics for CNS disorders. This breakthrough could accelerate development of treatments for Alzheimer’s and other tauopathies, addressing a significant unmet medical need.
What we're watching
- Clinical Validation
- Whether Arrowhead can replicate these results in Alzheimer’s patients and other tauopathies.
- Regulatory Pathway
- The pace at which Arrowhead advances discussions for additional indications.
- Competitive Positioning
- How this breakthrough solidifies Arrowhead’s leadership in CNS-targeted RNAi therapies.
Related topics
